Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors December 20, 2024 Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next ...

COURT: D.N.J. TRACK DOCKET: No. 2:25-cv-00713 (Bloomberg Law subscription) A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...

A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot CagriSema caused economic damage after patients lost less weight using the ...

The Allegations: Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo's Phase 3 CagriSema Study on Obesity About Robbins LLP ...

Investors had dumped Novo shares in late December when data on a highly touted experimental Novo weight-loss shot called CagriSema fell far short of the expectations the company had set.

Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...

A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little//File Photo · Reuters / Reuters The company ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

In late December, Novo Nordisk announced that its much anticipated next-generation obesity drug CagriSema had missed its target for patients to lose 25 per cent of their body weight in a late ...

Novo’s CagriSema is a once-a-week injection that combines cagrilinitide, a novel amylin analog, with semaglutide. Amylin analogs slow down the rate at which food empties from the stomach into ...

Novo is already licking its wounds from another setbackits experimental two-drug combo, CagriSema, underwhelmed in trials, landing at 22.7% weight loss, barely moving the needle against Zepbound.